University Hospitals of Leicester Nhs Trust

Rejuvenate Biomed Initiates Phase II Trial of RJx-01 for COPD-Related Muscle Weakness

6 days ago

• Rejuvenate Biomed has dosed the first subject in a randomized Phase II trial evaluating RJx-01 for muscle weakness and sarcopenia in COPD patients, addressing a condition with no currently approved treatments. • The double-blind, placebo-controlled study will enroll 130 older adults hospitalized with severe acute COPD exacerbation, measuring the drug's impact on muscle strength, physical function, and fatiguability. • RJx-01 previously demonstrated improvements in muscle strength and function in Phase I trials, targeting multiple cellular pathways related to muscle quality decline including mitochondrial health.

UK Expands Clinical Trial Access with New Research Hubs

5 months ago

• The UK government is investing £100 million in 20 new Commercial Research Delivery Centres (CRDCs) across the country. • These hubs will focus on conditions like cancer, obesity, infectious diseases, and aim to provide access to cutting-edge treatments. • The CRDCs will facilitate clinical trials in underserved regions, allowing more people to participate in medical research. • The initiative is a joint public-private investment to boost the UK's life sciences sector and stimulate economic growth.

Rejuvenate Biomed Partners with NIHR Leicester BRC for Phase 2 Trial of Novel COPD-Related Sarcopenia Treatment

7 months ago

• Rejuvenate Biomed, University of Leicester, NIHR Leicester BRC, and Wellcome Leap have partnered to conduct a Phase 2 clinical trial evaluating RJx-01 for COPD-related sarcopenia, with patient enrollment expected to begin in the first half of 2025. • The double-blind placebo-controlled trial will assess RJx-01's safety and efficacy in 130 older individuals hospitalized with severe acute COPD exacerbations, focusing on maintaining muscle integrity and improving physical function. • RJx-01 previously demonstrated promising results in a Phase 1b trial, showing meaningful improvements in muscle strength, function, and fatigue resistance in people with disuse-induced muscle weakness.